Figure 5.

Zalcitabine suppresses pancreatic tumor growth via autophagy-dependent ferroptosis in vivo. (A) NOD SCID mice were injected subcutaneously with the indicated PANC1 cells (5 × 10⁶/mouse) and treated with zalcitabine (50 mg/kg per day by i.p.) at day 7 for 2 weeks. Tumor volume was calculated weekly (n = 5 mice/group, data expressed as means ± SD, *P < 0.05, ANOVA LSD test). (B, C) In parallel, the levels of MDA (B) and ACSL4 (C) in the isolated tumors at day 28 were assayed by ELISA (n = 5 mice/group, *P < 0.05, ANOVA LSD test). (D) NOD SCID mice were injected subcutaneously with PANC1 cells (5 × 10⁶/mouse) and treated with zalcitabine (50 mg/kg per day by i.p.) in the absence or presence of H-151 (750 nM per mouse, once every other day by i.p.), chloroquine (50 mg/kg once every other day by i.p.), or liproxstatin-1 (10 mg/kg once every other day by i.p.) at day 7 for 2 weeks. Tumor volume was calculated weekly (n = 5 mice/group, data expressed as means ± SD, *P < 0.05, ANOVA LSD test). (E, F) In parallel, the levels of MDA (E) and ACSL4 (F) in the isolated tumors at day 28 were assayed by ELISA (n = 5 mice/group, *P < 0.05, ANOVA LSD test)